Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2

The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely sym...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Pharmacol
Asıl Yazarlar: Kaur, Upinder, Acharya, Kumudini, Mondal, Ritwick, Singh, Amit, Saso, Luciano, Chakrabarti, Sasanka, Chakrabarti, Sankha Shubhra
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier B.V. 2020
Konular:
Full Length Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485553/
https://ncbi.nlm.nih.gov/pubmed/32926917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejphar.2020.173545
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller